FDA Approves New Melanoma Combo, ASH Abstracts Released, Early Ovarian Cancer Data, and More

The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.

The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.

With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.

New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.